Johnson & Johnson

06/12/2021 | Press release | Distributed by Public on 06/12/2021 05:51

New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult[...]